Reimagining women's health • Hybrid healthcare • Focused on non-communicable diseases11-50 Employees
- Early StageStartup in initial stages
Nabta Health careers
Nabta Health (nabtahealth.com) discovers new ways for women to prevent, identify and manage non-communicable diseases (NCDs).
The growing epidemic of NCDs threatens the ambition of countries around the world to achieve sustainable, universal access to health and universal health coverage for their populations. NCDs also leave populations more susceptible to communicable diseases such as COVID-19.
Moreover, NCDs remain underesearched and underserved in women. Until the mid-1990s, clinical research and clinical trials largely excluded women. Today, women using drugs that were approved pre-1994, are 50–75% more likely than men to suffer adverse reactions to those therapies. Ironically, a significant proportion of the drugs in this category are those designed to treat or manage NCDs. Examples include statins and potassium channel-blockers used to manage cardiovascular disease or hypoglycaemic drugs such as Rezulin used to control diabetes.
Standardising and personalising the ways in which women identify and manage NCDs in the context of their own lifestyles and health goals, and through the use of applied machine learning and Artificial Intelligence, will improve clinical outcomes and make cutting-edge healthcare affordable and accessible for all women.
Nabta’s unique model of hybrid healthcare seamlessly combines digital health with traditional healthcare to improve health outcomes in women living with NCDs.
Nabta’s first hybrid care pathway supports women in preventing, identifying and managing Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal disorder responsible for 70% of female fertility issues. Women who use Nabta’s platform will be able to obtain a formal diagnosis of PCOS within 90 days versus the global average of 2.5 years.
The growing epidemic of NCDs threatens the ambition of countries around the world to achieve sustainable, universal access to health and universal health coverage for their populations. NCDs also leave populations more susceptible to communicable diseases such as COVID-19.
Moreover, NCDs remain underesearched and underserved in women. Until the mid-1990s, clinical research and clinical trials largely excluded women. Today, women using drugs that were approved pre-1994, are 50–75% more likely than men to suffer adverse reactions to those therapies. Ironically, a significant proportion of the drugs in this category are those designed to treat or manage NCDs. Examples include statins and potassium channel-blockers used to manage cardiovascular disease or hypoglycaemic drugs such as Rezulin used to control diabetes.
Standardising and personalising the ways in which women identify and manage NCDs in the context of their own lifestyles and health goals, and through the use of applied machine learning and Artificial Intelligence, will improve clinical outcomes and make cutting-edge healthcare affordable and accessible for all women.
Nabta’s unique model of hybrid healthcare seamlessly combines digital health with traditional healthcare to improve health outcomes in women living with NCDs.
Nabta’s first hybrid care pathway supports women in preventing, identifying and managing Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal disorder responsible for 70% of female fertility issues. Women who use Nabta’s platform will be able to obtain a formal diagnosis of PCOS within 90 days versus the global average of 2.5 years.
General Application: Roles in Selling and Marketing to HR OFFICERS
Onsite or remote • Dubai • London • United Kingdom+12 more
د.إ133k – د.إ266k • No equityDr. Saba Alzabin
Dr. Mussaad Al-Razouki
Founder at Kleos Health, @GlamboxME, @AbiDoc and @MEDtrip Former @Columbia Surgeon and Management Consultant
CBDO at Kuwait Life Sciences Company, part of NTEC
Sophie Smith
Co-founder and CEO of Nabta Health • Serial impact entrepreneur • Strong business and technology background (@Accenture) • Cambridge BA 2010 • MBA 2018.